Last reviewed · How we verify
Amyvid
At a glance
| Generic name | Amyvid |
|---|---|
| Also known as | [18F]Florbetapir, 18F-Florbetapir |
| Sponsor | Invicro |
| Target | Amyloid beta A4 protein |
| Modality | Small molecule |
| Therapeutic area | Rare Disease |
| Phase | FDA-approved |
Approved indications
- Positron emission tomography
Common side effects
- Headache
- Musculoskeletal pain
- Blood pressure increased
- Nausea
- Fatigue
- Injection site reaction
- Anxiety
- Back pain
- Claustrophobia
- Dizziness
- Feeling cold
- Insomnia
Key clinical trials
- Alzheimer's Disease Neuroimaging Initiative 4
- Biomarker Exploration in Aging, Cognition and Neurodegeneration (PHASE3)
- Imaging Cardiac Amyloidosis: A Pilot Study Using F-18 Florbetapir Positron Emission Tomography (PHASE4)
- A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)
- Neuronavigation-guided FUS-induced BBB Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and Tau (PHASE1)
- Effects of Brain Beta-Amyloid on Postoperative Cognition (PHASE4)
- Autopsy Follow-up of Subjects Previously Imaged With Florbetapir F 18 (18F-AV-45) PET in Trial 18F-AV-45-A07 (PHASE3)
- Plasma P-tau2017 and Quantitative Amyloid PET Imaging (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amyvid CI brief — competitive landscape report
- Amyvid updates RSS · CI watch RSS
- Invicro portfolio CI